AVROBIO, Inc. (AVRO): Price and Financial Metrics
AVRO Price/Volume Stats
| Current price | $16.80 | 52-week high | $17.28 |
| Prev. close | $1.42 | 52-week low | $0.88 |
| Day low | $16.56 | Volume | 17,233 |
| Day high | $17.28 | Avg. volume | 269,831 |
| 50-day MA | $1.34 | Dividend yield | N/A |
| 200-day MA | $1.38 | Market Cap | 754.22M |
AVRO Stock Price Chart Interactive Chart >
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
AVRO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -7.28% |
| 1-year | 10.24% |
| 3-year | -68.61% |
| 5-year | -91.51% |
| YTD | 2.94% |
| 2023 | 90.77% |
| 2022 | -81.48% |
| 2021 | -72.38% |
| 2020 | -30.75% |
| 2019 | 20.90% |
Loading social stream, please wait...